Uncoupling protein 2 modulation of the NLRP3 inflammasome in astrocytes and its implications in depression

Redox Biology

Volumn 9, Issue , 2016, Pages 178-187

  Du, Ren Hong ^a   Wu, Fang Fang ^a   Lu, Ming ^a   Shu, Xiao dong ^a   Ding, Jian Hua ^a   Wu, Guangyu ^b   Hu, Gang ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Astrocyte; Depression; NLRP3 inflammasome; Reactive oxygen species; Uncoupling protein 2

Indexed keywords

CRYOPYRIN; INFLAMMASOME; REACTIVE OXYGEN METABOLITE; THIOREDOXIN INTERACTING PROTEIN; UNCOUPLING PROTEIN 2; CARRIER PROTEIN; THIOREDOXIN; TXNIP PROTEIN, MOUSE;

ADULT; ANHEDONIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL LOSS; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HIPPOCAMPUS; KNOCKOUT MOUSE; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL BEHAVIOR; GENETICS; METABOLISM; NERVOUS SYSTEM DEVELOPMENT;

ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; CARRIER PROTEINS; DEPRESSION; HIPPOCAMPUS; INFLAMMASOMES; MALE; MICE; MICE, KNOCKOUT; NEUROGENESIS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXINS; UNCOUPLING PROTEIN 2;

EID: 84983460407     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.08.006     Document Type: Article

References (47)

1. [1] Cai, N., Bigdeli, T.B., Kretzschmar, W., Li, Y., Liang, J., Song, L., et al. Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature 523 (2015), 588–591.
2. [2] Kokacya, M.H., Bahceci, B., Bahceci, I., Dilek, A.R., Dokuyucu, R., Prolidase activity and oxidative stress in patients with major depressive disorder. Psychiatr. Danub 26 (2014), 314–318.
3. [3] Tobe, E.H., Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatr. Dis. Treat. 9 (2013), 567–573.
4. [4] Wang, H., Warner-Schmidt, J., Varela, S., Enikolopov, G., Greengard, P., Flajolet, M., Norbin ablation results in defective adult hippocampal neurogenesis and depressive-like behavior in mice. Proc. Natl. Acad. Sci. USA 112 (2015), 9745–9750.
5. [5] Slavich, G.M., Irwin, M.R., From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol. Bull. 140 (2014), 774–815.
6. [6] Hashioka, S., Miyaoka, T., Wake, R., Furuya, M., Horiguchi, J., Glia: an important target for anti-inflammatory and antidepressant activity. Curr. Drug Targets 14 (2013), 1322–1328.
7. [7] Dong, X.H., Zhen, X.C., Glial pathology in bipolar disorder: potential therapeutic implications. CNS Neurosci. Ther. 21 (2015), 393–397.
8. [8] Reus, G.Z., Fries, G.R., Stertz, L., Badawy, M., Passos, I.C., Barichello, T., et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300 (2015), 141–154.
9. [9] Norman, G.J., Karelina, K., Zhang, N., Walton, J.C., Morris, J.S., Devries, A.C., Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Mol. Psychiatry 15 (2010), 404–414.
10. [10] Konsman, J.P., Veeneman, J., Combe, C., Poole, S., Luheshi, G.N., Dantzer, R., Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. Eur. J. Neurosci. 28 (2008), 2499–2510.
11. [11] Koo, J.W., Duman, R.S., Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci. Lett. 456 (2009), 39–43.
12. [12] Rethorst, C.D., Toups, M.S., Greer, T.L., Nakonezny, P.A., Carmody, T.J., Grannemann, B.D., et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry 18 (2013), 1119–1124.
13. [13] Broderick, L., De Nardo, D., Franklin, B.S., Hoffman, H.M., Latz, E., The inflammasomes and autoinflammatory syndromes. Annu Rev. Pathol. 10 (2015), 395–424.
14. [14] Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4 (2015), 296–307.
15. [15] Guo, H.C., Jin, Y., Zhi, X.Y., Yan, D., Sun, S.Q., NLRP3 inflammasome activation by viroporins of animal viruses. Viruses 7 (2015), 3380–3391.
16. [16] Luna-Gomes, T., Santana, P.T., Coutinho-Silva, R., Silica-induced inflammasome activation in macrophages: role of ATP and P2X7 receptor. Immunobiology 220 (2015), 1101–1106.
17. [17] Suarez, R., Buelvas, N., Inflammasome: activation mechanisms. Investig. Clin. 56 (2015), 74–99.
18. [18] Zhou, R., Tardivel, A., Thorens, B., Choi, I., Tschopp, J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11 (2010), 136–140.
19. [19] Alcocer-Gomez, E., Ulecia-Moron, C., Marin-Aguilar, F., Rybkina, T., Casas-Barquero, N., Ruiz-Cabello, J., et al. Stress-Induced Depressive Behaviors Require a Functional NLRP3 Inflammasome. Mol. Neurobiol., 2015 Sep 11. [Epub ahead of print].
20. [20] Lee, H.J., Hong, Y.S., Jun, W., Yang, S.J., Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of Type 2 diabetes. J. Med. Food 18 (2015), 1207–1213.
21. [21] Ruscitti, P., Cipriani, P., Di Benedetto, P., Liakouli, V., Berardicurti, O., Carubbi, F., et al. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1beta via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin. Exp. Immunol. 182 (2015), 35–44.
22. [22] Heneka, M.T., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493 (2013), 674–678.
23. [23] Coll, R.C., Robertson, A.A., Chae, J.J., Higgins, S.C., Munoz-Planillo, R., Inserra, M.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21 (2015), 248–255.
24. [24] Ozaki, E., Campbell, M., Doyle, S.L., Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J. Inflamm. Res. 8 (2015), 15–27.
25. [25] Willems, P.H., Rossignol, R., Dieteren, C.E., Murphy, M.P., Koopman, W.J., Redox homeostasis and mitochondrial dynamics. Cell Metab. 22 (2015), 207–218.
26. [26] Toda, C., Diano, S., Mitochondrial UCP2 in the central regulation of metabolism. Best Pract. Res Clin. Endocrinol. Metab. 28 (2014), 757–764.
27. [27] Lu, M., Sun, X.L., Qiao, C., Liu, Y., Ding, J.H., Hu, G., Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation. Neurobiol. Aging 35 (2014), 421–430.
28. [28] Wu, Z., Zhao, Y., Zhao, B., Superoxide anion, uncoupling proteins and Alzheimer's disease. J. Clin. Biochem. Nutr. 46 (2010), 187–194.
29. [29] Haines, B.A., Mehta, S.L., Pratt, S.M., Warden, C.H., Li, P.A., Deletion of mitochondrial uncoupling protein-2 increases ischemic brain damage after transient focal ischemia by altering gene expression patterns and enhancing inflammatory cytokines. J. Cereb. Blood Flow Metab. 30 (2010), 1825–1833.
30. [30] Kong, H., Sha, L.L., Fan, Y., Xiao, M., Ding, J.H., Wu, J., et al. Requirement of AQP4 for antidepressive efficiency of fluoxetine: implication in adult hippocampal neurogenesis. Neuropsychopharmacology 34 (2009), 1263–1276.
31. [31] Lu, M., Zhao, F.F., Tang, J.J., Su, C.J., Fan, Y., Ding, J.H., et al. The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels. Antioxid. Redox Signal 17 (2012), 849–859.
32. [32] Maes, M., Song, C., Yirmiya, R., Targeting IL-1 in depression. Exp. Opin. Ther. Targets 16 (2012), 1097–1112.
33. [33] Wen, H., Miao, E.A., Ting, J.P., Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 39 (2013), 432–441.
34. [34] Gao, J., Liu, R.T., Cao, S., Cui, J.Z., Wang, A., To, E., et al. NLRP3 inflammasome: activation and regulation in age-related macular degeneration. Mediat. Inflamm., 2015, 690243.
35. [35] Kim, J.J., Jo, E.K., NLRP3 inflammasome and host protection against bacterial infection. J. Korean Med. Sci. 28 (2013), 1415–1423.
36. [36] Sun, B., Wang, X., Ji, Z., Li, R., Xia, T., NLRP3 inflammasome activation induced by engineered nanomaterials. Small 9 (2013), 1595–1607.
37. [37] Heid, M.E., Keyel, P.A., Kamga, C., Shiva, S., Watkins, S.C., Salter, R.D., Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J. Immunol. 191 (2013), 5230–5238.
38. [38] Liu, Y., Lian, K., Zhang, L., Wang, R., Yi, F., Gao, C., et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res. Cardiol., 109, 2014, 415.
39. [39] Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 11 (2010), 897–904.
40. [40] Mohamed, I.N., Hafez, S.S., Fairaq, A., Ergul, A., Imig, J.D., El-Remessy, A.B., Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia 57 (2014), 413–423.
41. [41] Sun, X.L., Liu, Y., Dai, T., Ding, J.H., Hu, G., Uncoupling protein 2 knockout exacerbates depression-like behaviors in mice via enhancing inflammatory response. Neuroscience 192 (2011), 507–514.
42. [42] Rothhammer, V., Quintana, F.J., Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol. 37 (2015), 625–638.
43. [43] Rajkowska, G., Stockmeier, C.A., Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug Targets 14 (2013), 1225–1236.
44. [44] Banasr, M., Chowdhury, G.M., Terwilliger, R., Newton, S.S., Duman, R.S., Behar, K.L., et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 15 (2010), 501–511.
45. [45] Jo, W.K., Zhang, Y., Emrich, H.M., Dietrich, D.E., Glia in the cytokine-mediated onset of depression: fine tuning the immune response. Front. Cell Neurosci., 9, 2015, 268.
46. [46] Phillips, E.C., Croft, C.L., Kurbatskaya, K., O'Neill, M.J., Hutton, M.L., Hanger, D.P., et al. Astrocytes and neuroinflammation in Alzheimer's disease. Biochem. Soc. Trans. 42 (2014), 1321–1325.
47. [47] Gliem, M., Krammes, K., Liaw, L., van Rooijen, N., Hartung, H.P., Jander, S., Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia 63 (2015), 2198–2207.